Rosetta Genomics, NYU Add Neonatal Heart Disorder to miRNA Cancer Alliance | GenomeWeb
NEW YORK (GenomeWeb News) — Rosetta Genomics has added congenital neonatal cardiovascular disease to a collaboration with the New York University School of Medicine that was originally created to use miRNA technology to develop cancer diagnostics, the company said today.
  
Rehovot, Israel-based Rosetta Genomics said the research will screen for specific miRNA biomarkers and signatures that could help diagnose or target congenital heart disease in newborns.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.